To date, four therapies have been approved for the targeting of HER2-positive breast cancer: two antibodies (trastuzumab and pertuzumab), an antibody-drug conjugate (ado-trastuzumab emtansine), and a small molecule kinase inhibitor (lapatinib) [8]. The gene discussed is ERBB2; the disease is breast cancer.